

# ENHANCING PALLIATIVE CARE IN INTENSIVE CARE UNITS (EPIC) TRIAL – DESIGN OF THE HEALTH ECONOMIC SUB-STUDY

EE412

EPIC  
ENHANCING PALLIATIVE CARE IN INTENSIVE CARE UNITS

Michaela Carla Barbier, PhD<sup>1</sup>; Spyridon Mentzelopoulos, Prof.<sup>2</sup>; Andreas Edel, MD<sup>3</sup>; Martin Neukirchen, Prof.<sup>4</sup>; Katerina Rusinova, MD<sup>5</sup>; Jochen Dutzman, Priv.-Doz. MD<sup>6</sup>; Akiva Nachshon, MD<sup>7</sup>; Edoardo De Robertis, Prof.<sup>8</sup>; Sophie K. Piper, PhD<sup>9</sup>; Susanne Joebges, MD<sup>3</sup>; Claudia Spies, Prof.<sup>3</sup>; Victoria Metaxa, MD<sup>10</sup>; Christiane S. Hartog, Prof. MD<sup>11</sup>; Matthias Schwenkglenks, Prof. PhD<sup>1</sup>

<sup>1</sup>Institute of Pharmaceutical Medicine (ECPM) and Health Economics Facility, Department of Public Health, University of Basel, Basel, Switzerland, <sup>2</sup>First Department of Intensive Care Medicine, National and Kapodistrian University of Athens Medical School, Evangelismos Hospital, Athens, Greece, <sup>3</sup>Department of Anaesthesiology and Intensive Care Medicine, Charité Universitätsmedizin, Berlin, corporate member of Freie Universität Berlin und Humboldt-Universität zu Berlin, Berlin, Germany,

<sup>4</sup>Interdisciplinary Centre for Palliative Medicine, Medical Faculty, interdisciplinary Centre for Palliative Medicine, Medical Faculty, University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany, <sup>5</sup>Department of Palliative Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic, <sup>6</sup>Clinique for Internal Medicine III, University Hospital Halle, Halle (Saale), Germany, <sup>7</sup>General Intensive Care Unit, Department of Anesthesia, Critical Care and Pain Medicine, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel, <sup>8</sup>Section of Anaesthesia Analgesia and Intensive Care, Department of Medicine and Surgery, University of Perugia, Perugia, Italy, <sup>9</sup>Charité- Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Medical Informatics and Institute of Biometry and Clinical Epidemiology, Charitéplatz 1, Berlin, Germany, <sup>10</sup>Department of Critical Care, King's College Hospital NHS Foundation Trust, London, United Kingdom, <sup>11</sup>TP21 Berlin and Charité Universitätsmedizin Berlin, Berlin, Germany.


## Background EPIC trial

- Aims to assess blended learning and integration of specialized palliative care into intensive care via telemedical consultations.
- Is intensive care unit (ICU) length of stay reduced and care for critically ill non-cancer patients improved?
- We present the design of the health economic sub-study, aiming to evaluate cost implications and cost-effectiveness of the intervention.




## Methods

- EPIC is a European, stepped-wedge cluster randomised trial conducted in 7 clinical centers and 30 multidisciplinary intensive care units in 5 European countries (Greece, Czech Republic, Italy, Israel, and Germany). Each clinical center is a "hub" that provides specialist consultations to 2 to 5 more distant intensive care units, which act as "satellite centers".
- N=2001 patients anticipated. Enrolment since October 2024. Last patient last visit expected September 2027.
- The intervention includes early and high-quality access to palliative care through
  - telemedical consultations by experts from external institutions specialized in palliative care provided to ICU staff
  - training of ICU staff in basic palliative care
  - use of checklists for early identification of eligible patients and structured recording of palliative care needs.
- Health economic data collection items were determined and tailored-to-purpose through literature review, consultations with consortium experts and financial departments of participating centres.
- Cost and value for money of the complex intervention compared to standard care will be studied from healthcare system, societal and institutional perspectives. The latter will consider reimbursements and costs at the hospital level.
- Given challenges of interpreting standard cost-effectiveness metrics (costs per quality-adjusted life year gained) in our setting, costs will also be related to other trial outcomes in a cost-consequence analysis.



## Fig. 2 Primary endpoint, EQ-5D and cost measurements



## Results

- Health-related quality-of-life (HRQoL) is assessed using appropriate language versions of the EQ-5D-5L questionnaire, completed by patients or proxies. A mixture of retrospective and current-day EQ-5D-5L measurements covers the period from 14 days before ICU admission to 3 months post ICU discharge (see Figs. 1 & 2). Follow-up data is collected during telephone interviews from surviving patients and/or patients' relatives including HRQoL, use of health services and resources.
- Given variability in reimbursement and accounting systems in the five recruiting countries, collection of patient-level and reimbursement data, and site-level unit cost data, is being pursued as consistently as feasible.
- Patient-level cost and billing data are provided by hospital administrations. Variables collected at the patient level will cover reimbursements and real costs for the period from start of index hospitalization to 3-month follow-up (including flat-fee reimbursement codes if applicable) (Fig. 2).
- Medical resource use data, including relevant admission and discharge dates, are extracted from clinical information systems by study staff (until the end of index hospitalization), or self-reported by patients and relatives (from end of index hospitalization to the 3-month follow-up). This information will be combined with unit costs from publicly accessible, external sources or hospital administrations.
- Information on productivity losses and informal care is also self-reported.
- The costs of the intervention will be estimated considering the cost of telemedicine technology (based on information from centres and/or technology providers), staff time (for training, palliative care consultations) and staff costs per unit of time, by relevant profession.
- Data monitoring quality checks are defined and ongoing, as a basis for corrective action if required.

## Conclusions

- We have implemented a pragmatic, feasible strategy for health economic data collection in a complex trial setting.
- Ensuring data quality and completeness requires continuous monitoring to identify needs for corrective action.
- The economic findings may help identify barriers to palliative care integration and facilitate larger-scale implementation.

The project is funded by the European Union's HORIZON Europe research and innovation programme under Grant number 101137221 by the Swiss State Secretariat for Education, Research and Innovation (under contract number 24 00021) and by the UKRI grant number 10115894. Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency. Neither the European Union nor the European Health and Digital Executive Agency can be held responsible for them. No conflicts of interest are declared.

Funded by the European Union

UKRI

Innovate UK

On behalf of the EPIC Consortium

Project funded by

Schweizerische Eidgenossenschaft  
Confédération suisse  
Confederazione Svizzera  
Confederaziun svizra  
Swiss Confederation

Federal Department of Economic Affairs,  
Education and Research EAER  
State Secretariat for Education,  
Research and Innovation SERI

Universität Basel | Department of  
Public Health  
Health Economics Facility

Contact information

michaela.barbier@unibas.ch